In vitro colon cancer assays demonstrated that FGFR2 signaling promotes PD-L1 expression through the JAK/STAT signaling pathway and is not affected by mammalian target of rapamycin (mTOR) or MAPK signaling [89]. The gene discussed is MTOR; the disease is malignant colon neoplasm.